Biotech Duo to Unveil New Data on Klotho Anti-Aging Therapy

LAS VEGAS, NV – April 07, 2026 – In the burgeoning field of longevity science, few targets have generated as much excitement as the α-Klotho protein. Now, a joint venture between emerging biotech firm Avaí Bio and cell therapy specialist Austrianova is poised to take center stage, announcing plans to present the latest data from their innovative Klotho-based anti-aging therapy at a major scientific conference this September.

The presentation, scheduled for the Second Annual Klotho Conference, will offer a glimpse into a novel approach that aims to restore declining levels of this crucial “longevity protein.” By using encapsulated living cells to create a sustainable, internal source of Klotho, the companies hope to unlock a new frontier in the treatment of age-related disorders, moving the concept of anti-aging from science fiction closer to clinical reality.

The “Longevity Protein” at the Heart of the Quest

First discovered in 1997 by Dr. Makoto Kuro-o, who will be a featured speaker at the upcoming conference, the Klotho gene immediately captured the attention of the scientific community. Mice engineered to lack the gene exhibited a syndrome of accelerated aging, suffering from conditions like vascular calcification, osteoporosis, and cognitive decline, and living significantly shorter lives. Conversely, mice engineered to overexpress Klotho lived over 30% longer than their normal counterparts.

Subsequent research has revealed that α-Klotho is a multifunctional protein that acts as a master regulator of aging. Its levels naturally decline as we age, and this decline is strongly correlated with a host of age-related diseases, including chronic kidney disease, neurodegenerative conditions like Alzheimer's, and cardiovascular ailments. The protein exists in both a membrane-bound form, primarily in the kidneys, and a soluble form that circulates throughout the body, acting as a hormone that suppresses multiple pathways linked to aging, inflammation, and oxidative stress.

Developing a therapy based on this protein, however, is fraught with challenges. Directly administering a large, complex protein like Klotho can be difficult due to its instability and short half-life in the bloodstream, requiring frequent and potentially costly injections. This is the precise problem that the joint venture, named Klothonova, aims to solve.

A Novel Delivery System: The Cell-in-a-Box® Approach

At the core of Klothonova's strategy is Cell-in-a-Box®, a proprietary cell encapsulation technology developed by Austrianova. This innovative platform involves placing genetically modified cells, engineered to produce the α-Klotho protein, inside a semi-permeable, biocompatible capsule. These tiny capsules, which can be implanted in the body, act as miniature bioreactors.

The capsule’s membrane is designed to be a selective barrier. It allows essential nutrients to flow in to keep the cells alive and functioning, while permitting the therapeutic Klotho protein they produce to be released into the bloodstream in a continuous, stable manner. Crucially, the membrane shields the encapsulated cells from the patient's immune system, preventing rejection without the need for lifelong immunosuppressant drugs.

This approach offers a potential paradigm shift for biologic drug delivery. Instead of intermittent external doses, the body would have a long-term, internal factory for its own supply of the therapeutic protein. Austrianova has already been advancing this technology, and in March, the partners announced the production of a Master Cell Bank for their Klotho therapy under Good Manufacturing Practice (GMP) standards—a critical step on the path toward clinical trials.

"We look forward to sharing the latest data from Klothonova's progress in α-Klotho production from encapsulated cells at this prestigious forum," said Brian Salmons, Chief Executive Officer of Austrianova, in a statement. "We are honored to be invited... to participate in this conference and to present the latest data on production of α-Klotho using Cell-in-a-Box® alongside our peers."

Navigating the High-Stakes Longevity Market

The collaboration highlights the strategic maneuvering within the rapidly growing, high-stakes longevity market. Avaí Bio, an emerging publicly-traded company (OTCQB: AVAI), is leveraging a partnership model to gain access to cutting-edge technology. The company, which recently rebranded from Avant Technologies to sharpen its focus on cell-based therapies, is betting that this joint venture can position it as a serious contender in the anti-aging space.

However, they are not alone. The therapeutic potential of Klotho has attracted other players. Klotho Neurosciences, Inc. is developing its own Klotho-based therapies for neurodegenerative diseases, and larger companies are exploring related anti-aging pathways, from senolytics that clear out aging cells to NAD+ boosters that target cellular metabolism.

Klothonova's unique delivery system may provide a key competitive advantage, but the path forward for any novel cell-based therapy is long and arduous. It involves extensive preclinical testing, navigating a complex regulatory landscape overseen by agencies like the FDA, and ultimately proving both safety and efficacy in multi-phase human clinical trials. For an emerging company like Avaí Bio, success hinges not only on scientific validation but also on the ability to secure the significant capital required to fund this long development process.

A Glimpse into the Future at the Klotho Conference

The presentation at the Second Annual Klotho Conference represents a significant milestone. This specialized forum brings together the world’s foremost experts, investors, and clinicians focused on this single protein. Presenting data here provides not just visibility but also an opportunity for critical peer review from the very scientists who laid the groundwork for this field.

The presence of Dr. Kuro-o and other leaders underscores the scientific community's intense interest in translating the promise of Klotho from the laboratory to the clinic. Rahul Pawa, Austrianova’s Chief Production Officer, will be tasked with convincing this discerning audience that the Cell-in-a-Box® approach is a viable and potentially superior method for harnessing Klotho's power.

The data shared in September will be scrutinized for details on the efficiency of protein production, the stability and longevity of the encapsulated cells, and the safety profile observed in preclinical models. While a commercial therapy is still years away, this presentation will serve as a crucial indicator of progress, potentially paving the way for future clinical trials and shaping the ongoing scientific and ethical conversations about what it means to treat the process of aging itself.